By Kelly Cloonan
Shares of Skye Bioscience rose after the company announced promising preclinical data for a drug combination including its new CB1 antibody nimacimab.
The stock was up 60% to $2.09 Tuesday. Shares have lost 84% over the past 12 months.
The biotechnology company said nimacimab combined with tirzepatide resulted in greater than 30% weight loss for mice in a diet-induced obesity model over 25 days.
Nimacimab alone demonstrated 24% weight loss, comparable with monlunabant and tirzepatide alone, the company said.
Chief Executive Punit Dhillon said data supports the company's belief that its antibody approach can provide meaningful efficacy without the risk of unwanted neuropsychiatric side effects that come with small molecule CB1 inhibitors like monlunabant.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
April 15, 2025 12:31 ET (16:31 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。